UNICREDIT BANK/CALL/CARL ZEISS MEDITEC/150/0.1/19.03.25 Stock

Warrant

DE000HD3ZW87

Market Closed - BOERSE MUENCHEN 03:45:35 2024-05-24 pm EDT
0.08 EUR -11.11% Intraday chart for UNICREDIT BANK/CALL/CARL ZEISS MEDITEC/150/0.1/19.03.25
Current month-61.90%
1 month-63.64%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-24 0.08 -11.11%
24-05-23 0.09 -10.00%
24-05-22 0.1 -16.67%
24-05-21 0.12 0.00%
24-05-20 0.12 -7.69%

Real-time BOERSE MUENCHEN

Last update May 24, 2024 at 03:45 pm EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying CARL ZEISS MEDITEC AG
IssuerLogo Issuer UniCredit UniCredit
WKN HD3ZW8
ISINDE000HD3ZW87
Date issued 2024-03-21
Strike 150
Maturity 2025-03-19 (298 Days)
Parity 10 : 1
Emission price 0.62
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.64
Lowest since issue 0.013
Spread 0.1
Spread %62.50%

Company Profile

Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.
Sector
-
More about the company

Ratings for Carl Zeiss Meditec AG

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Carl Zeiss Meditec AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
15
Last Close Price
92.35 EUR
Average target price
103.9 EUR
Spread / Average Target
+12.47%
Consensus